Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: sailor who wrote (8250)	5/21/1998 8:11:00 AM
From: Zebra 365	Read Replies (1) \| Respond to of 23519

MUSE approved in South Africa MOUNTAIN VIEW, Calif.--(BW HealthWire)--May 21, 1998--VIVUS, Inc. (NASDAQ:VVUS) today announced that MUSE(R) (alprostadil) has been approved by the South African Medicine Control Council for sale and distribution by Janssen Pharmaceutica. MUSE is currently cleared for commercial distribution and has been launched in the United States and the United Kingdom. Approvals have also been received for Sweden, Argentina, Brazil, South Korea and Switzerland. Astra AB and Janssen Pharmaceutica will distribute and market the product outside the United States and VIVUS will be the exclusive manufacturer of MUSE for domestic and international markets from its manufacturing facilities in Lakewood, New Jersey. "VIVUS is pleased to announce today the first approval for MUSE in Africa," said Leland Wilson, President and Chief Executive Officer. "VIVUS looks forward to South Africa leading the way with their approval of MUSE, as Africa represents a large, important market." Janssen expects to launch MUSE in South Africa before the end of the summer. Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile dysfunction, commonly referred to as impotence. VIVUS has pioneered a novel therapy for erectile dysfunction known as MUSE(R) (alprostadil). This therapy consists of a proprietary, non-invasive drug delivery system that delivers pharmacologic agents via the urethra. -0- Note to editors: MUSE is a registered trademark of VIVUS, Inc. Additional written materials, recent releases and company information are available through a variety of sources, including: the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719). CONTACT: VIVUS Nina W. Ferrari or David Yntema, 650/934-5200